Monday, February 12, 2001
In many chronic indications, the advantage of drug versus placebo tends
to blur over time. Thus QLT Inc. was pleasantly surprised when Phase IIIb data for its
Visudyne verteporfin photodynamic therapy in age-related macular degeneration showed
greater benefit at two years than at one year.
The trial was in patients with AMD caused by occult subfoveal choroidal
neovascularization (CNV) without classic components. These data, along with Phase IIIb
data for patients with CNV due to pathologic myopia, could more than double the target
patient population for Visudyne, which is approved in the U.S. and Europe to treat
predominantly classic subfoveal CNV caused by AMD.